-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Cell therapy represented by stem cells and immune cells is attracting widespread attenti.
In 2021, two domestic CAR-T cell therapy drugs, Akilenxe Injection and Ruikiolenxe Injection, will be launched one after anoth.
Entering 2022, cell therapy has entered a new stage of developme.
The industry generally believes that a new era of cell therapy has arrived, and the future of the entire market is promisi.
The market prospect of cell therapy equipment is promising, and domestic enterprises are constantly striving for automation (Source: PharmaNet) In this new era of cell therapy, as domestic cell therapy products are launched one after another and gradually move towards commercialization, the upstream cell therapy The equipment industry will also usher in development opportunities, and at the same time face higher challenges, including increasing production capacity, controlling costs, e.
, equipment companies need to continuously upgrade technology in order to meet the high-quality development needs of the indust.
At present, automation and standardization are regarded by the industry as the development trend of the cell therapy equipment industry, especially the application of automation technology, which can replace the traditional manual and semi-automatic methods and greatly improve the production efficiency and product quality of cell thera.
In this context, many pharmaceutical machine companies are making continuous efforts in new directio.
For example, pharmaceutical machine companies have continuously upgraded their technology through in-depth layout over the years, and currently can provide a full range of automated stem cell separation and storage equipme.
producti.
Organic pharmaceutical companies use isolator technology as a platform technology to integrate key instruments and equipment required for cell drug preparation, which can realize complete station functions such as separation and extraction, induction and activation, expansion culture, liquid exchange, and collection, and realizes the transformation from cell dru.
The seamless connection between R&D and GMP production of cell drugs realizes the closed operation of the whole process and prevents cross-contamination in the production proce.
Tofflon also mentioned on the interactive platform that the company has continued to invest in cell preparation and other fields to improve its overall turnkey engineering capabilities and help the company to sustainably grow its mid- and long-term business performan.
In addition, Chutian Technology recently mentioned in an institutional survey, "The automation equipment has basically relied on imports before, and the domestic production is mainly semi-automat.
The company's plan is to develop fully automatic products, and launch prototypes in the second half of the year, as the company's new product development this ye.
It is expected to break the import monopo.
" At present, domestic and foreign companies are actively seizing the commanding heights of the cell therapy industry, trying to share the market ca.
However, as far as the domestic situation is concerned, cell therapy equipment generally relies on imports, and it also requires the continuous efforts of domestic enterprises to continuously break the bottleneck and help the better development of China's cell therapy indust.
Policy assistance will support the further development of the cell therapy industry, among which cell therapy and clinical transformation have been included in the "14th Five-Year Plan" development plan, which will release more vitality of the cell therapy market and create huge space for developme.
According to Frost & Sullivan, the size of China's cell therapy market will increase from 3 billion yuan in 2021 to 54 billion yuan in 2030, with an average annual growth rate of 5
Another data shows that China's cell and gene therapy market is expected to reach US$59 billion in 2025, growing at a compound growth rate of 27
In general, in the future, leading pharmaceutical machine companies with innovation and R&D capabilities are expected to gain greater opportunities for developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In 2021, two domestic CAR-T cell therapy drugs, Akilenxe Injection and Ruikiolenxe Injection, will be launched one after anoth.
Entering 2022, cell therapy has entered a new stage of developme.
The industry generally believes that a new era of cell therapy has arrived, and the future of the entire market is promisi.
The market prospect of cell therapy equipment is promising, and domestic enterprises are constantly striving for automation (Source: PharmaNet) In this new era of cell therapy, as domestic cell therapy products are launched one after another and gradually move towards commercialization, the upstream cell therapy The equipment industry will also usher in development opportunities, and at the same time face higher challenges, including increasing production capacity, controlling costs, e.
, equipment companies need to continuously upgrade technology in order to meet the high-quality development needs of the indust.
At present, automation and standardization are regarded by the industry as the development trend of the cell therapy equipment industry, especially the application of automation technology, which can replace the traditional manual and semi-automatic methods and greatly improve the production efficiency and product quality of cell thera.
In this context, many pharmaceutical machine companies are making continuous efforts in new directio.
For example, pharmaceutical machine companies have continuously upgraded their technology through in-depth layout over the years, and currently can provide a full range of automated stem cell separation and storage equipme.
producti.
Organic pharmaceutical companies use isolator technology as a platform technology to integrate key instruments and equipment required for cell drug preparation, which can realize complete station functions such as separation and extraction, induction and activation, expansion culture, liquid exchange, and collection, and realizes the transformation from cell dru.
The seamless connection between R&D and GMP production of cell drugs realizes the closed operation of the whole process and prevents cross-contamination in the production proce.
Tofflon also mentioned on the interactive platform that the company has continued to invest in cell preparation and other fields to improve its overall turnkey engineering capabilities and help the company to sustainably grow its mid- and long-term business performan.
In addition, Chutian Technology recently mentioned in an institutional survey, "The automation equipment has basically relied on imports before, and the domestic production is mainly semi-automat.
The company's plan is to develop fully automatic products, and launch prototypes in the second half of the year, as the company's new product development this ye.
It is expected to break the import monopo.
" At present, domestic and foreign companies are actively seizing the commanding heights of the cell therapy industry, trying to share the market ca.
However, as far as the domestic situation is concerned, cell therapy equipment generally relies on imports, and it also requires the continuous efforts of domestic enterprises to continuously break the bottleneck and help the better development of China's cell therapy indust.
Policy assistance will support the further development of the cell therapy industry, among which cell therapy and clinical transformation have been included in the "14th Five-Year Plan" development plan, which will release more vitality of the cell therapy market and create huge space for developme.
According to Frost & Sullivan, the size of China's cell therapy market will increase from 3 billion yuan in 2021 to 54 billion yuan in 2030, with an average annual growth rate of 5
Another data shows that China's cell and gene therapy market is expected to reach US$59 billion in 2025, growing at a compound growth rate of 27
In general, in the future, leading pharmaceutical machine companies with innovation and R&D capabilities are expected to gain greater opportunities for developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
